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STUDY QUESTION: Is it feasible to undertake a randomised controlled trial to establish whether surgical removal of endometrioma or not,
improves live birth rates from IVF?
SUMMARY ANSWER: A randomised controlled trial (RCT) comparing surgery versus no surgery to endometrioma prior to IVF is only
feasible in UK if an adaptive rather than traditional study design is used; this would minimise resource wastage and complete the trial in an
acceptable time frame.
WHAT IS KNOWNALREADY: There is wide variation in the management of endometriomas prior to IVF, with decisions about treatment
being influenced by personal preferences.
STUDY DESIGN, SIZE, AND DURATION: This was a mixed-methods study consisting of an online survey of clinicians, a focus group
and individual interviews with potential trial participants.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometriosis and fertility experts across the UK were invited to participate
in an online anonymised questionnaire. Potential future trial participants were recruited from a tertiary care fertility centre and invited to
participate in either individual interviews or focus groups.
MAIN RESULTS AND THE ROLE OF CHANCE: Clinicians and potential trial participants confirmed the need for an RCT to inform the
management of an endometrioma prior to IVF. There were 126 clinicians who completed the survey, and the majority (70%) were willing to
recruit to a trial. Half of those who responded indicated that they see at least 10 eligible women each year. The main barriers to recruitment
were waiting lists for surgery and access to public funding for IVF. One focus group (n =7) and five interviews were conducted with potential
trial participants (n =3) and their partners (n =2). The findings from these discussions highlighted that recruitment and retention in a potential
RCT could be improved by coordination between IVF and surgical services such that an operation does not delay IVF or affect access to public
funding. Live birth was considered the most important outcome with an improvement of at least 10% considered the minimum acceptable by
both patients and clinicians.
LIMITATIONS, REASONS FOR CAUTION: This feasibility study captured views of clinicians across the UK, but as patients were from a
single Scottish centre, their views may not be representative of other areas with limited public funding for IVF.
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WIDER IMPLICATIONS OF THE FINDINGS: There is a need for an appropriately powered RCT to establish whether or not surgical
treatment of endometrioma prior to IVF improves live birth rates. There are logistical issues to be considered due to limited number of
participants, funding of IVF andwaiting times. These could be overcome in a RCT by using an adaptive design whichwould include a prospectively
planned opportunity for modification of specified aspects of the study design based on interim analysis of the data, coordination of IVF
treatments and endometriosis surgeries and international collaboration. Similar principles could be used for other questions in fertility where
a traditional approach for randomised trials is not feasible.
STUDY FUNDING/COMPETING INTEREST(S): Funding was received from the NHS Grampian R&D pump priming fund (RG14437-
12). S.B. is Editor-in-Chief of HROPEN, and A.W.H. is Deputy Editor of HROPEN. Neither was involved in the review of this manuscript.
L.S. reports grants from CSO and NIHR to do endometriosis research, outside the submitted work. K.C. reports grants from NIHR/HTA and
CSO during the conduct of the study. J.H.e., A.W.H., J.D., S.B.r., K.B., G.B., J.H.u. and K.G. report no conflict of interest.
Key words: endometrioma / endometriosis / IVF / live birth / surgery
WHAT DOES THIS MEAN FOR PATIENTS?
Endometriosis is a condition where tissue similar to the womb lining is found in other parts of the body. It can cause fertility problems, and
women may need treatments such as in vitro fertilisation (IVF). About a third of women with endometriosis have cysts called endometriomas
which are often removed before starting IVF to try to improve the chances of success. It is possible, however, that removing endometriomas
could make IVF less likely to work. Researchers want to carry out a trial to see whether removing endometriomas before IVF is a good idea.
They consulted doctors and patients and realised it would be difficult to get enough people to take part in a traditional trial as IVF funding is
often limited and it would mean delays in treatment. Instead of a traditional trial, they would rather use a more flexible type of study where you
can start with small numbers of participants and adapt the study from what you learn as you go. It means you can change what you expect to
find as you get more evidence. This paper proposes using this kind of trial to work out whether surgery for endometriomas is beneficial.
Introduction
Endometriosis affects 1 in 10 women of reproductive age, 30–40%
of whom experience infertility (Redwine, 1999) and 17–44% have an
endometrioma. “”Many of these women require in vitro fertilisation
(IVF) for treatment of their infertility.
Surgical removal or ablation of an endometrioma prior to IVF has
traditionally been believed to prevent exacerbation of disease, reduce
the dose of gonadotrophins required for ovarian stimulation, reduce
the risk of infection during oocyte retrieval and bring down treatment
costs. Removing an endometrioma can also provide a histological diag-
nosis which helps to rule out rare cases of malignancy. It is also possible
that the procedure may also improve the chances of spontaneous
conception.
Data from more recent studies suggest that surgery (and the need
for postsurgical recovery) for endometrioma can delay IVF treatment.
Additionally, some reports suggest that surgical damage to ovarian
tissue can compromise ovarian reserve (Raffi et al., 2012a, Somigliana
et al., 2012) leading to fewer oocytes and lower success rates. This
is disputed by other studies which have failed to show a similar effect
(Muzii et al., 2014).
Consequently, there is considerable uncertainty at the present time
(Dunselman et al., 2014; Hamdan et al., 2015) about whether oper-
ating on an endometrioma prior to IVF is beneficial or not. A single
randomised controlled trial (n =99) has failed to show improved preg-
nancy rates after surgery (Demirol et al., 2006), but surgical treatment
of endometriosis and endometrioma(s) prior to IVF continues to be
widely practiced (Raffi et al., 2012b), despite its attendant risks and
costs.
Improving fertility in women with endometriomas is one of the
top 10 priorities identified by the James Lind Alliance priority setting
partnership for endometriosis (Horne et al., 2017). Following repeated
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calls from clinicians, patients and policymakers to address this uncer-
tainty, a well-designed adequately powered, randomised controlled
trial (RCT) evaluating the effectiveness of surgery on endometrioma
prior to IVF is overdue. We searched various trial registries (ISRCTN;
ANZCTR; ChiCTR) for ongoing/proposed trials; only one trial was
found registered in 2008 (ISRCTN35880386) which was stopped after
a year (personal communication (T Gelbaya). This was conducted
unfunded in a single centre. Another protocol was published recently
(Tomassetti et al., 2018), but the trial was never conducted. The major
challenges to date are the complexity of designing and conducting a
successful trial and limited numbers of eligible participants.
These illustrate that it is a difficult trial to recruit and traditional trial
designs may not be appropriate. We conducted a study to determine a
feasible design of a future multicentre RCT of surgery for endometri-
oma prior to IVF in UK.
Materials and Methods
In order to assess the feasibility of an RCT, we undertook a survey of
clinicians’ views and conducted a focus group, followed by individual
interviews with potential trial participants. It was anticipated that the
combined views from these two groups would provide information on
key components of a future trial including the choice of participants,
intervention, comparison and outcomes, sample size, likely accrual rate
and duration of trial and optimum trial design to enhance recruitment
and retention.
Clinicians’ survey
SurveyMonkeyTM software was used to create an online survey for
completion by fertility and endometriosis specialists. Appropriate steps
were taken to construct this questionnaire such as relevant wording,
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sequencing and consideration of time taken to complete it. A simple
self-administered online survey was constructed to assess: minimal
non-identifying baseline demographic data; prevalence and current
practices of managing endometrioma in women undergoing IVF; treat-
ment preferences using four clinical scenarios each describing two
alternative approaches to endometrioma prior to IVF (drainage of
endometrioma and ablation of base versus excision, complete excision
of endometrioma versus partial excision, aspiration of endometrioma
under ultrasound guidance versus aspiration at laparoscopy or use
of medical treatment using a GnRH agonist before and after surgery
versus no GnRH agonist); willingness to recruit to a trial of pre-
stated/any clinical scenarios; barriers to recruitment and retention in a
trial; and preferred primary outcome.
There was space for free comments at the end to capture any further
thoughts not covered in the above sections. The questionnaire was
peer-reviewed by two experts to assess content validity and readability.
It was piloted amongst five experts who were advised to ‘think aloud’
as a cognitive probe in the presence of a researcher to assess the face
validity of the questions.
Clinicians were asked to quantify current levels of clinical certainty
on a 5-point linear scale (definitely prefer A, may prefer A, unde-
cided, may prefer B, definitely prefer B) about alternative treatment
approaches (with a variety of available techniques and approaches to
treat endometrioma) in controversial clinical scenarios. This was to
assess and quantify the strength of their preferences for treatment
approaches and assess equipoise at the level of the clinician (individual
equipoise) and within the clinical community (community equipoise)
(Young et al., 2006).
Administering the questionnaire
An email containing a link to the questionnaire with a covering
letter was sent to two groups of clinicians (fertility specialists and
endometriosis experts). The lead clinician of each centre in the UK
was sent a personalised email with a covering letter and a link to the
survey with request to forward the survey to all clinicians in their unit.
The contact details of each IVF centre are publicly available on the
Human Fertilisation and Embryology Authority (HFEA) website. A
reinforcement email was also sent through the Reproductive Medicine
Clinical Studies Group (RMCSG), North of England Reproductive
medicine Group, Scottish Fertility Group and the Principal Investigators
of two ongoing clinical trials (E-Freeze: ISRCTN-61225414 and
PreEMPT: ISRCTN-97865475). The questionnaire was also sent to
all British Society of Gynaecological Endoscopy (BSGE) members via
the British Society of Gynaecology Endoscopy (BSGE) secretary.
Focus group and individual interviews
A focus group and individual interviews were conducted with women
(and where appropriate their partners) to explore trial acceptability
amongst potential participants, investigate views on trial recruitment
and retention and identify outcomes most relevant to them. Women
who were potentially eligible to participate in the proposed trial were
identified from the Aberdeen Fertility Centre (a tertiary centre for
the North of Scotland). Women and partners were invited to take
part in the feasibility study by the treating clinicians and were sent an
invitation pack. A topic guide for both the interviews and the focus
group were developed in consultation with patient and partners. It
explored the following areas: background knowledge; willingness to
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take part in an RCT; barriers to research participation (specifically
to an RCT); retention in proposed trial; preferred outcomes; and
presentation of information about the RCT. Interviews and the focus
group were audio-recorded and transcribed verbatim.
Ethical approval was obtained by North of Scotland Research
Ethics committee (Ref number—IRAS: 245259; R&D Reference—
RG14437-12).
Data analysis
Clinicians’ survey
Data were summarised descriptively using numbers and percentages.
Responses between the types of specialists were compared using
Fisher’s exact test as the expected frequencies were less than five.
Analyses were performed in Stata 15 software (StataCorp 2017. Stata
Statistical Software: Release 15. College Station, TX: StataCorp LLC).
Focus group and individual interviews
Data were coded and analysed using a Template Analysis variation of
thematic analysis to incorporate the inductive and deductive nature of
the interviews (Brooks et al., 2015). The initial thematic framework
focused on practical aspects for trial design and delivery. This was
developed by J.H. then reviewed by K.G. for consistency and further
refinement. This framework was then applied consistently across all
transcripts.
As this was a feasibility study a formal sample size calculation was not
done.
Results
Clinicians’ survey
There were 126 responses to the questionnaire, of which 59 (47%)
were from endometriosis specialists and 67 (55%) were from fertility
specialists. Most offered both publicly (NHS) funded as well as privately
funded treatment.
The annual number of women with pre IVF endometriomas cared
for by each clinician varied: 22 (17%) reported seeing 8–10 women, 66
(52%) saw more than 10 women, and the remainder managed fewer
than 8 women per year. The responses from fertility and endometriosis
experts were similar.
The diameter of an endometrioma below which the specialists
would withhold surgery also varied, with the majority choosing 3 cm
(29%) or 4 cm (25%) as cut-off values. There were some differences
between the two groups of gynaecologists, as fewer endometriosis
specialists (22% versus 13%) had a size threshold. In the free comments
section, several endometriosis specialists mentioned that they acted as
technicians at request of their IVF colleagues who actually made the
decision to operate. Most specialists stated that they would prefer to
proceed straight to IVF rather than surgery in women over the age
of 40.
Current preferences and recruitment to a trial
To explore current practices (to determine equipoise) and identify
the interventions to compare in a trial, specific questions were asked
(Table I) for the following interventions. There was no difference
between the two groups of specialists in terms of current practices
or willingness to recruit to an RCT comparing the two interventions.
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Laparoscopic treatment or transvaginal aspiration. Most respondents
(n =114, 90%) preferred laparoscopic treatment when compared to
transvaginal aspiration with no difference between the two group of
specialists (88 vs 92%, P value 0.529). For randomising participants to
an RCT comparing these two interventions, 38% said yes and 31% said
no with 17% being undecided.
Laparoscopic excision or laparoscopic drainage and ablation of base.
There were 88 (70%) who preferred laparoscopic excision. For recruit-
ing to an RCT, 70% said yes with no difference between the specialists
(P value 0.510).
Laparoscopic complete excision or laparoscopic partial excision. Three
quarters of respondents (n =94, 75%) preferred laparoscopic com-
plete excision. There was a mixed response for randomising partici-
pants to an RCT, with 41% saying yes, 23% saying no and 21% were
undecided.
Pre-operative GnRH agonist or no pre-operative GnRH agonist. Half
of the respondents preferred no pre-operative GnRH agonist. For
recruiting to a trial on this, 47% would participate, 19% would not
participate and 24% were undecided.
Post-operative GnRH agonist or no post-operative GnRH agonist. The
proportions of respondents who preferred to use post-operative
GnRH agonist (41%) treatment were similar to those who did not
(36%). Over half of the respondents (52%) were willing to recruit
participants to an RCT comparing post-operative versus no post-
operative GnRH agonist.
Willing to randomise to any trial comparing treatments to endometrioma.
When asked if they would be willing to randomise to any trial com-
paring treatments to endometrioma, 62.4% indicated that they would,
while 20% were undecided.
Primary outcome
Clinicians in both groups were asked to choose a preferred primary
outcome out of clinical pregnancy, live birth or healthy baby rate. Most
agreed that live birth rate was the preferred primary outcome (61%).
Just over half the respondents (55%) agreed that >10% improvement
in the primary outcome would be acceptable in the context of an RCT,
7% indicated that it should be >15% whereas 25% were content with
a 5–7% improvement. According to the clinicians, the proportion of
eligible women who might be willing to participate in an RCT varied
from less than 25% to 50–75%. A third thought that women would be
willing to be followed up.
Identified barriers for recruitment and retention
When asked about barriers to recruitment and retention in the trial,
the concerns raised by both group of clinicians in free text were:
NHS waiting lists for surgery leading to delay in accessing IVF; different
specialists carrying out surgery and IVF; and availability of public funding
for IVF. Endometriosis surgeons specifically advised that decision is
usually made by fertility clinicians.
Focus group and individual interviews
A total of 12 participants (nine women and three men) were recruited
to participate in individual interviews or focus groups between Octo-
ber and December 2018. It was important to involve couples as any
infertility treatment involves both partners. Three individual interviews
were with women, one was a joint interview with both partners
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and one focus group (consisting of five women and two men) was
conducted. Interviews lasted between 60 and 120 min.
Six main themes emerged from the exploratory work with potential
trial participants. Each of these key areas is discussed in detail below.
Acceptability of the research question
All participants felt that the research question ‘surgery or no surgery
for endometrioma prior to IVF’ was important.
P2 ‘Because if the doctors don’t know and you don’t know then
there’s no real . . . you can’t really make a decision because you don’t
know what’s going on really do you. So the more information you have
the more evidence there is, you’re able to make better choices.’
Participants acknowledged that the requirement for this research
was to improve treatment options and improve decision-making in
this context. It was accepted that participating in a clinical trial was ‘a
gamble’ but noted that high-quality data was needed to enable patients
to make well-informed choices in the future.
P7 ‘For future people going through this because I think once you’ve
been through anything first hand you have empathy for anybody who
is going to go through it in the future. So if, I suppose if we, or if I can
be involved in something that is going to bring somebody up another
step towards that goal then yes, I would be involved.’
P11 ‘But like I said, if I could help in any kind of study then I would,
just because . . . I just would. Yeah, I just would.’
Timing of the invitation to participate in trial
There was consensus amongst all patients that introduction and recruit-
ment to a trial should be as close to diagnosis of endometrioma
(and any recommendation for IVF) as possible. The timeliness of
this approach was considered important as the process of fertility
investigations and treatments can become stressful and overwhelming
very quickly, leaving little reserve for consideration of trial participation.
Inviting women at diagnosis would foster feelings of ‘doing something
to support their IVF’ as well as build on the momentum of developing a
treatment plan, being active participants rather than passive recipients
of care.
P1 ‘Yeah, as soon as you know that you’re going to get IVF, strike
while the iron is hot. Let couples think about it from the beginning,
“We could be a part of a trial, we don’t know what side we’re going
to be on but it’s going to be a trial, we know all the options.’
P7 ‘Yeah, I agree, probably at that start, at the first scan . . . because
you’re still full of zip and you know, you think, “Okay, great, yeah, okay,
we’re going to do that, yeah, I’ll be part of that, that’s fine.’
Women identified that they expect decisions (about treatment and
trial participation) to be made in conjunction with their partners.
Partners expressed the view that that even in the unlikely event they
disagreed about trial participation they would support the woman’s
preferences.
Waiting times for surgery
Participants had mixed feelings about waiting times about surgery,
especially in areas where they had to wait for IVF as well. Participants
asserted that ‘knowing what would happen and when’ was of greater
importance than delays from waiting lists. It is noteworthy that patients
suggested an upper threshold of 3 months for any additional wait time
on the trial. Their reservations would likely be resolved through clear
and open communication about why this delay existed/was necessary.
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P3 ‘I think what I was saying, if you’re telling me today, “Hello, you
can be part of . . . if you’re not part of this trial you’re waiting a year to
have IVF because there’s the waiting list”, I would say, “Okay, this is the
waiting list in NHS’, ‘If you take part in this trial”, if you’re not going to
make my year longer I will take part you know, or you make it longer
by a few months, you know what I mean.’
P1 [standardisation of wait times] ‘I think you would get way more
people to come on board, not that they knowwhat one they’re going to
get, way more people would know that within six months “I’ve had my
operation, recovered and I’m going through IVF” and the other people
is “I’m going straight into IVF, I’ll hopefully have a baby at the end of
nine months and then I’ll have my operation” Yeah, I think you’d get
more people.’
P5 ‘The brackets for IVF are sort of under 35, 35 to 38, 38 and above
or thereabouts. So anything that goes within six months to a year that
already moves you from one bracket, potentially to one bracket to the
next, so that would be too much I think. Anything that goes over you
know, around half a year or so.’
P10 ‘So yeah, I don’t know. I think it [standardising wait times across
all trial centres] would help you to maybe recruit more people.’
P11 ‘Once you get to the stage that we’re at you don’t care! The E-
Freeze thing as well, when we signed up for it we were thinking we’ve
waited so long anyway, what’s another couple of months or whatever
going to . . . you know, what’s an extra couple of months? It’s nothing
really, compared to what we’ve been through already, it would be silly
not to do it.’
P12 ‘I don’t know what it’s like for other people but we’ve had a
fairly long journey to this point and so time, I think, is already going to
be something that’s on people’s minds no matter what age you are, just
in terms of how long you’re going through this stuff. Not necessarily in
terms of running out of time for having a baby and so to know that that
wouldn’t be dragged out any longer than necessary would be a really
positive thing, definitely.’
Confidence in the clinical team
All participants identified confidence in their clinical team as a key influ-
encer to participating in a RCT. Most participants felt that a member
of the clinical team rather than academic team should introduce the
trial. However, being knowledgeable about the trial and being able
to answer questions competently would be key for their decision-
making about participating. Participants asserted that honest and com-
prehensive communication from outset about the risks and benefits
of treatments including waiting times and deviations from standard
pathways, supports them in feeling in control and in making informed
decisions.
P10 ‘I suppose probably the consultant in a way because then you
can ask them more medical questions about how it might impact your
treatment, and then maybe the researcher because then you could ask
practical questions about the research, and then maybe the nurse. But
I don’t have a . . . I don’t think I would have strong, what’s the word,
preferences. I think as long as I knew who I could speak to if I wanted,
if I needed more information.’
P8 ‘So I think ultimately you have to be extremely clear what you’re
asking people to do, I think that’s probably the key thing at the start.’
P3 ‘From my point of view it doesn’t really matter who gives me
the information, if I have questions as long as that person knows what
they’re talking about. I guess if you’re there and you have the scan,
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which will be done by a doctor, a consultant, whatever, they’ll probably
just mention it, “Oh, by the way we have this trial, and would you like
to know more information?”’
Additionally, if trial staff were unable to be sensitive to the patients’
emotional state and acknowledge the challenging context of balancing
a diagnosis with an invitation to participate in a trial, this would also
reduce their willingness to participate.
P1 ‘I think as long as you explain it, you make it all very clear and it’s
not complicated because when things start getting complicated then
people are like, they’re not really bothered, they don’t want to do it.
They just want to get to that end goal’.
P12 ‘Yeah, I guess it’s a sensitivity and an understanding to people’s
individual situations. And I guess understanding that sometimes phone
calls might come at the wrong time, might have to wait, that kind of
thing. Conversations . . . maybe kind of a choice that they say, “No,
I don’t want to have that conversation now but next week might be
better,” that kind of thing. It’s a particularly emotional time.’
Patient characteristics as barriers to participation
The age of the patient may act as a potential delay to treatment
and may preclude them from accessing public funding for IVF due to
eligibility thresholds. Participants noted that the severity of their con-
dition may influence their decision to participate. They also indicated
that additional appointments would be unacceptable, especially when
considering associated travel distances and costs.
P1 ‘If you’ve got people coming as far as two hours away, I would try
to do it, have all of it on one day so they don’t have to keep toing and
froing.’
P2 ‘As long as it’s easy and its as seamless as possible and doesn’t
intrude too much . . . when things get a bit difficult is when people tend
to pull out... It’s when it becomes more complicated if you know what
I mean. People like to be easy.’
Trial retention
Potential participants indicated that if they signed up to a trial, they
would expect to remain committed to the trial until the end unless
there was a medical need to withdraw. Participants reported that any
trial in this area must run in parallel to typical clinic sessions for them
to consider participation. This continuity in their treatment pathway
would support them in feeling that the trial was not intruding on what
they already had to do in their ‘fertility journey’. Additionally, feeling
that participating in the trial improved their access to experts and peer
support would be a great incentive to initial decision to participate and
for continuation.
P2 ‘So people might see it as being a benefit I think is what you’re
trying to say . . . . . . people think it’s more of a benefit because they
think they’re going to get more of a specialist interaction maybe.’
P2 ‘Because once you’re invested, once you’ve signed up to
something you’ve invested in you’re quite happy to answer questions
because . . . . . . if I’ve joined up to a trial then when that trial finishes
is when I stop, not when I want, not when I would want to stop so to
speak.’
P10 ‘I think if you agree to take part in the trial then you’ve
already . . . like I can’t see why you would object to being contacted
again to get the benefit out of you having taken part. I suppose the
only . . . I guess if your pregnancy wasn’t successful then maybe you
wouldn’t want to be speaking to people.’
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P11 ‘No, I just know that if I’ve ever got a question they’re just at the
end of the phone.’
Outcomes of importance
Participants confirmed that live birth rate is the main outcome they
expect to measure success. Participants found it difficult to gauge the
level of improvement required to determine the level of success of
either surgery or no surgery before IVF. Estimates ranged between 3
and 30% with 10% being the modal value.
P3 ‘I guess is . . . obviously will want live birth as the outcome
because that’s what you want as an individual. Probably if you want
to find out whether this works or not you’d be looking more at maybe
implantation rate, because you know, if you lose the baby later on,
which we don’t want, then that might not have nothing to do with your
actual . . . actually your surgery, because you did the surgery to try to
get more follicles, more eggs, more embryos and you want to implant
them, that’s probably what the surgery will do.’
P10 ‘For me I don’t think it matters, a small increase, because I think
when you’re talking . . . like even if we say 15% and 20%, that’s massive,
I think that’s a massive increase in the chances of it being successful.’
P2 ‘If you said to me “it’s only 5%” I’d be like “Well that’s not really
anything really is it to be honest, it’s so small”.’
P3 ‘Oh, yeah, that’s definitely significant for me if it’s just like 10%
increase of . . . ’
Answers to specific questions posed by the
feasibility study
Based on the clinicians’ survey and qualitative work with potential
participants, it was clear that a randomised trial is needed.
The factors that would enhance recruitment and retention, identified
from this feasibility study could be divided in two groups: generic
and specific for this trial. The generic factors were good communica-
tion; ownership of decision-making by participants; impact on clinical
treatment; and extra travel. Specific factors related to surgery to
endometrioma to improve the outcome of IVF were: information
about trial early on in the infertility journey rather than at start of
IVF; very close liaison between the fertility and endometriosis team
so that every single eligible participant is approached for the trial; and
a joint pathway to bypass public (NHS) waiting lists for surgery, so that
patient care and eligibility for publicly funded IVF is not compromised
for those who agree to take part in trial. Bypassing waiting lists could be
justified as the number of participants would be small and it is important
that surgery is compared to no surgery in ideal circumstances (with no
delay) to determine if there is any benefit.
The components of the trial deduced from the feasibility study were:
population (women<40 years old undergoing IVF with endometrioma
of ≥3 cm, as below 3 cm and above 40 years of age there was
no equipoise); intervention (surgery to endometrioma followed by
IVF); comparator (IVF without prior surgery for endometrioma); and
outcomes: the primary outcome should be live birth.
Sample size calculation
The recommended improvement in live-birth rates after surgery was
at least 10%. Using traditional approach we would need to randomise
954 women for 90% power (two-sided alpha 5%) to detect a 10%
increase. For 80% power, we would need 712 women (Table II). This
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Table II Sample size calculation for proposed trial on surgery to endometrioma prior to IVF.
Control event rate Event rate in intervention group Power Enrolment ratio Sample required (total)
.......................................................................................................................................................................................
30% 40% 80% 1 712
30% 40% 90% 1 952
Table III Number available for recruitment (based on questionnaire) for proposed trial on surgery to endometrioma
prior to IVF from within UK.
No. of cases per year
from respondents of the
questionnaire
All respondents
recruiting
70% of all respondents
recruiting
Only Fertility specialist
recruiting only
70% of fertility
specialists recruiting
.......................................................................................................................................................................................
≥10 670 469 420 294
8–10 136 95.2 88 61.6
4–7 64 44.8 60 42
1–4 13 9.1 6 4.2
Total 883 618.1 574 401.8
50% recruitment 441.5 309.05 287 200.9
25% recruitment 220.75 154.52 143.5 100.45∗
∗Most pessimistic estimate
was based on assumption of 30% live birth rate (Human Fertilisation
and Embryology Authority, 2019) after one embryo transfer episode
in control group.
Likely accrual rate and duration of the trial
To assess the number of potential participants available in each UK
centre, we undertook some projections based on the responses from
the clinicians‘ survey (Table III). Using conservative estimates and the
most pessimistic scenario, we should be able to recruit a maximum
of 100 participants per year in the UK from the respondents’ clinics
(Table III). Hence, to recruit a minimum of 712 women, a minimum of
7 years will be needed. Given the minimum time needed for setting
up the study (6 months) and follow-up to live birth (18 months,
3 months to have surgery, 3 months to have IVF treatment, 9 months
for pregnancy and 3 months in case embryos are frozen and thawed
and transferred in subsequent cycles), a minimum of 9 years would be
needed to complete the RCT. This would increase to a minimum of
11 years, if the sample size was 952. This is clearly not expedient and
therefore not feasible. An international collaboration with recruitment
from multiple centres across the world would be ideal but is not
practical, due to existing patient pathways of care for surgery and IVF
in different countries as well as current systems of funding.
Suggested trial design
A limited number (i.e. 240) of eligible women can be recruited within
the UK over a reasonable recruitment period (30-month) (Table III). A
traditional trial design (Frequentist approach) with sample size calcula-
tion incorporating Type 1 and Type II error will not be feasible in this
situation as there is little adaptation permitted and it is a long process.
Hence, we need to think of non-traditional ways of doing this trial.
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Figure 1 Scope of adaptation following interim analysis in
adaptive clinical trial designs.
The literature for rare diseases was explored; however, by definition
a disease is called a rare disease when the prevalence is less than
1 in 2000. Endometrioma does not fulfil this criterion as at least
1 in 100 women undergoing IVF will have endometrioma. We also
explored the cancer literature for potential trial designs because sample
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Table IV Difference in Bayesian and Frequentist approach.
Frequentist Bayesian
.........................................................................................................................................................................................
Data varies (calculated on Type I & II errors) Data is fixed
Calculates P values & confidence interval Calculates credible interval
No previous data (‘prior’) Depends on prior and likelihood of observed data
Tends to be computationally less intensive Computationally intensive due to integration over many parameters
Figure 2 Suggested interim analysis points.
sizes are frequently restricted by the availability of participants. Two
potential strategies are commonly used that could also be useful IVF
trials in general, but specifically when sample size is restricted: adaptive
designs (in particular the group sequential design below) and Bayesians
approaches (Hampson et al., 2014). In general, adaptive designs include
prospectively planned opportunities for modification of one or more
specified aspects of the trial design based on interim analysis of
accumulating data. These modifications are made after the initiation
of the trial, are usually pre-specified so that the validity and integrity of
the study is not undermined. There are several types of adaptive trial
designs (Fig. 1).
For our specific scenario the group sequential design has clear
advantages. In group sequential trials, there are one or several pre-
planned interim analyses of data accumulating when recruitment is still
ongoing (Gsponer et al., 2014). At each interim analysis, a decision is
made about whether to continue with the trial or stop if early signals in
the data suggest a treatment is ineffective, known as stopping for futility.
However, a drawback of this approach in a more traditional, or Fre-
quentist, framework is that we pay a penalty for taking multiple looks
at the data. This inflates the Type I error, which requires changes to the
analysis, but has the consequence of making a trial larger (in general).
A Bayesian, rather than Frequentist, approach is better suited to
situations like this. Without mathematical details, a Bayesian approach
allows us to incorporate available information into a prior proba-
bility distribution, which is called the ‘prior’. As data from the trial
accumulates, it is combined with the prior to produce a posterior
probability distribution, which is known as the ‘posterior’ (Berry, 2006).
The posterior allows us to make intuitive probabilistic statements, for
example what is the probability of a specific size of treatment effect
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given the data in our trial (Gsponer et al., 2014). This is contrast to
a P value from a Frequentist analysis which gives us the probability of
finding the observed treatment effect (or one more extreme) given
that our null hypothesis (usually zero treatment effect) is true. Another
advantage is that that we pay no penalty for multiple interim looks at
the data, which makes Bayesian designs attractive when the number of
eligible participants is low. Some of the main differences between the
two approaches are given in Table IV.
A critique of Bayesian inference is that often a subjective prior is used.
Constructing prior distributions is not trivial, and not unexpectedly
different people may have different priors and therefore the same
data can deliver different posteriors and conclusions depending on
the choice of prior. However, this gets less likely as trial sample
size increases. Rather than a weakness, we see this a strength of
the Bayesian approach, by using different priors we can explore how
sensitive results are to the choice of prior. Although Bayesian and
adaptive designs are common in many other fields, we are not aware
of their use the field of fertility.
Given our primary outcome of live birth takes time to report,
we plan Interim futility analyses using an intermediate (or surrogate)
outcome (Goldman et al., 2008; Asakura et al., 2017). Interim futility
analyses will be based on clinical pregnancy (pregnancy at 7-week
gestation) as a surrogate outcome because it has desirable properties:
strongly correlatedwith and available 8months earlier than the primary
outcome of live birth.We suggest clinical pregnancy as the outcome for
interim futility analysis because without achieving clinical pregnancy one
cannot have live birth and most pregnancies continue once they reach
this stage (Braakhekke et al., 2014). A potential group sequential design
is shown in (Fig. 2). In a design like this, we would do three interim
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Figure 3 Suggested trial design (with interim analysis for futility).
analyses for futility based on clinical pregnancy rates after accrual of
30, 60 and 90 patients per arm at each stage. If the trial was not
stopped for futility, then a final analysis for efficacy would take place on
the full 240 participants using the primary outcome of live birth. We
anticipate a 35% clinical pregnancy rate in the control group (Human
Fertilisation and Embryology Authority, 2019; Miller et al., 2019). For
surgery to improve live-birth rates by 10%, one would expect to see
at least a 12% improvement in CPR i.e. from 35 to 47%, to account
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for any pregnancy losses (Coomarasamy et al., 2019). Interim futility
analyses on CPR will allow us to stop such a trial if probability that
the difference in the CPR is less than 12% is 90% or greater. The
trial can be stopped as surgery for endometrioma is not likely to
provide at least a 10% higher live birth than no surgery. In this way
the scarce research resources can be maximised, at the same time a
credible answer can be provided. A suggested trial design is illustrated
in Figure 3.
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Discussion
Principal findings
Our results show that, despite strong preferences, over two-thirds of
surveyed clinicians were willing to recruit to an RCT of surgery to
endometriomas prior to IVF but were concerned about NHS surgical
waiting lists and access to public funding for IVF. Women and their
partners in an exploratory qualitative study, as part of feasibility study
felt that the research question was important and were willing to
participate in an RCT but were anxious to avoid a delay in starting IVF
treatment. An improvement in live birth rate of at least 10% was the
most desired outcome.
The low numbers of eligible participants pose a major barrier
to recruitment to a conventional trial. We have suggested a non-
traditional design which requires lower numbers of eligible participants
to provide a credible answer in a limited time frame. Hence, we
recommend a Bayesian group-sequential design with live birth in an
IVF cycle as the primary outcome with interim futility analysis using
clinical pregnancy rate.
Strengths and limitations of our study
This is the first study assessing the feasibility of a randomised trial com-
paring clinical effectiveness of surgery versus no surgery for endometri-
oma in women prior to undergoing IVF. Our team had representation
from fertility specialists, endometriosis specialists, trial methodologists,
international experts in the field, qualitative researchers and patient
representatives. Our clinicians’ survey had equal participation from
endometriosis and fertility specialists.
Only 12 patients were interviewed in total. Participants consisted of
women and partner: individually and jointly. Being a feasibility study, a
formal power calculation was not needed.
This feasibility study had views of clinicians across the UK, but the
views of patients were from a small geographical area in Scotland.
Scotland has very good public funding for IVF; therefore, views may
not be representative of other regions of the UK where funding is
limited. We restricted to one centre for recruiting patients as process
are similar across Scotland, it was felt that addition of multiple centres
for exploratory qualitative study would add to the resources but not
the benefit.
Meaning of our findings
This proposed study on surgery to endometrioma prior to IVF is
unique in that although endometriosis affects a large proportion, but
this specific question is only relevant to a small group of popula-
tion. It is a treatment where public funding is restricted, outcome
depends on multiple factors including male partner and the treatment
spans over two specialist areas. This is why undertaking a tradi-
tional RCT would be difficult and possibly why it has not been con-
ducted despite continued debate in both fertility and endometriosis the
community.
The results from a survey of potential participants were predictable
in terms of their views which pertain to any trial such as adequate
honest, timely information and extra visits. Their own, and clinicians,
views specific to this trial were also predictable in terms of impact
of waiting lists and public funding on recruitment and retention in
.
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the trial. Very interesting is the minimum acceptable improvement in
live birth which was quoted as 10%. There is existing literature in the
field of IVF where both patients as well as clinicians would accept
a lower improvement in success rates as important (Scotland et al.,
2007). A larger improvement here may be due to the invasiveness
and complications associated with surgery, along with the delay to IVF.
What couples would be willing to trade of f to accept invasive nature
of the surgery will need to be further evaluated by larger studies and
methods such as Discrete Choice Experiments. This would ideally be
done alongside the proposed trial.
There is a lack of feasibility studies in the area of Reproductive
Medicine even though trials in this field are difficult, particularly the
ones where treatment pathway is affected. Feasibility studies represent
an attempt to get the question and design right prior to full funding so
avoiding the trap of supporting projects that ask the wrong questions
or not designed to be successfully completed. There is benefit overall
in doing feasibility studies (Morgan et al., 2018). The main purpose of a
feasibility study is to ‘de-risk’ potential full trial funding. Given difficulties
in recruiting to randomised trials, we would suggest doing feasibility
studies prior to planning an RCT. This will be certainly more attractive
to funders (Morgan et al., 2018).
In terms of trial designs in fertility where the number of participants
is limited but traditional trial designs require a large number to show a
meaningful benefit, it may be that we need to think of adaptive designs
to reduce uncertainty in clinical decision-making. Although live birth
should be the outcome to prove the effectiveness of the intervention,
there are possibilities where clinical pregnancy rates can be used to
identify ineffectiveness of expensive and invasive interventions to save
scarce research resources.
The Bayesian approach provides a formal framework for researchers
to incorporate prior knowledge and current evidence to derive new
probabilities for various hypotheses. Since the results are presented in
terms of probability, clinicians can interpret and apply research findings
to clinical practice directly (Wong and Warren, 2010).
Live birth is suggested as an outcome, but we have to determine the
time horizon as well. Ideally, cumulative live birth should be used but
there is inconsistency in the definition (Maheshwari et al., 2015) and
this will take a long time to calculate. Hence, for initial trial live birth
rate after first embryo transfer following randomisation could be used
as an outcome. At the same time, follow-up data should be collected
to determine cumulative live birth rate.
Conclusion
Clinicians and patients both support an appropriately powered RCT
to answer the research question ‘Should endometrioma be operated
prior to IVF to improve the livebirth rate’? However, due to limited
number of participants, complexity of public funding arrangements
for IVF as well as waiting lists for surgery, traditional randomised trial
designs would not be appropriate.We suggest using a group sequential
Bayesian approach with interim analysis for futility for this as well as
other trials in field of Reproductive Medicine. This would certainly
reduce the uncertainty in decision-making where evidence is lacking
currently and trials are difficult to design. We also highlight the need
for close cooperation and communication between professionals to
ensure recruitment and retention in this challenging study. Feasibility
studies must be done prior to designing trials to minimise resource
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wastage. Although live birth can be used in initial trial, arrangements
should be made for follow-up to determine cumulative live birth rate.
For a randomised trial comparing surgery versus no surgery prior to
IVF in women with endometrioma, we recommend a Bayesian group-
sequential design with live birth in an IVF cycle as the primary outcome
with interim futility analysis using clinical pregnancy rate.
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